Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda, Astellas, Shimadzu Join To Develop iPS-Based Drugs

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical, Astellas Pharma and Shimadzu have signed an agreement with Kyoto University to develop ways to use stem cells created from adult skin in Japan. University investigators have produced pluripotent stem cells from skin. The cells are capable of growing into nerves and muscles, important in advancing regenerative medicine. Under the four-party agreement, the two drug makers are to use medical-equipment maker Shimadzu's laboratory equipment to test their drug compounds for effectiveness and toxicity, with the hope of using the iPS cells to develop new drugs within five years. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067192

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel